Posted by Michael Wonder on 24 Sep 2024
Ipsen’s Kayfanda (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
23 September 2024 - E.U. marketing authorization for Kayfanda based on data from ASSERT the only Phase 3 trial completed in patients with Alagille syndrome.
Ipsen today announced that the European Commission has approved Kayfanda (odevixibat) under exceptional circumstances for the treatment of cholestatic pruritus in Alagille syndrome in patients aged 6 months or older.
